We’re delighted to share BioMonde’s feature during our partner Yamni Nigam’s appearance on the ITV News Face to Face series, which profiles leading innovators from across Wales.
In the interview, Yamni discusses her pioneering research with BioMonde while showcasing our unique BioBag technology for treating chronic wounds. She highlights how the product is manufactured at our Bridgend headquarters and supplied to hospitals, pharmacies, and clinics worldwide. She also shares more insight into the collaboration currently underway at BioMonde, which explores the untapped potential of larval secretion and its ability to help prevent antibiotic resistance:
“Some very exciting news is that the secretion that we know contains all these wonderful molecules that help the maggot get rid of dead tissue, that help the maggot cure infection. We know there’s 47 different antibiotics in the maggots each week. They’re amazing, absolutely amazing. So, we could harness that and use that as a treatment. And in fact, the medical company that creates the maggots has recently decided to delve into that. And I’m actually supervising their R&D project manager at the moment to create something.”– Professor Yamni Nigam
This exciting discovery would help to address the growing concern over antibiotic overuse and its threat to the effectiveness of healthcare systems worldwide. Yamni and our R&D team are currently exploring this new field of biomedical research that will help shape the future of modern medicine. Our head of R&D Project Manager, Micah Flores, PhD, FRES comments on Yamni’s work and on-going partnership at BioMonde:
“Yamni has been instrumental in the advancement of research on larval therapy and future larval therapy derived products. In fact, current research efforts on maggot’s antibiotic-rich secretions at BioMonde are being supervised by Yamni, myself, and another professor at Swansea University as part of one of our R&D Project Manager’s PhD Thesis. She has shaped the future researchers in this important field not only with her own research efforts but through the knowledge she enthusiastically provides to her students and through her outreach.”
The ongoing research – developed in collaboration with our R&D team – has benefited from Yamni’s wealth of experience within the Larval Therapy space. Together, we look forward to addressing the growing global challenge of antibiotic resistance and advancing future research in larval therapy.